CN Patent

CN117462525B — 衣康酸在治疗坏死性小肠结肠炎患者中的应用

Assigned to Guangzhou First Peoples Hospital · Expires 2024-11-15 · 2y expired

What this patent protects

本发明提供了衣康酸在治疗坏死性小肠结肠炎患者中的应用。本发明经过研究发现，衣康酸能明显改善坏死性小肠结肠炎新生鼠的肠上皮绒毛上皮细胞结构，改善肠道损伤。因此，衣康酸可用于治疗新生儿坏死性小肠结肠炎，减轻患儿进展为重症坏死性小肠结肠炎的可能，减少手术可能性，尽可能避免手术后带来的短肠综合征等外科手术后遗症。

USPTO Abstract

本发明提供了衣康酸在治疗坏死性小肠结肠炎患者中的应用。本发明经过研究发现，衣康酸能明显改善坏死性小肠结肠炎新生鼠的肠上皮绒毛上皮细胞结构，改善肠道损伤。因此，衣康酸可用于治疗新生儿坏死性小肠结肠炎，减轻患儿进展为重症坏死性小肠结肠炎的可能，减少手术可能性，尽可能避免手术后带来的短肠综合征等外科手术后遗症。

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: CN117462525B
Jurisdiction: CN
Classification: —
Expires: 2024-11-15
Drug substance claim: No
Drug product claim: No
Assignee: Guangzhou First Peoples Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.